☆ 4.6 Review

The therapeutic landscape of tauopathies: challenges and prospects

ALZHEIMERS RESEARCH & THERAPY (2023)

Related references

Note: Only part of the references are listed.

Article Radiology, Nuclear Medicine & Medical Imaging

Associations between near end-of-life flortaucipir PET and postmortem CTE-related tau neuropathology in six former American football players

Michael L. Alosco et al.

Summary: This study examined the association between end-of-life flortaucipir PET and postmortem neuropathological measurements of CTE-related tau. The results suggest that Flortaucipir-PET could be useful for detecting high stage CTE neuropathology, but its specificity to CTE p-tau is uncertain. In vivo biomarkers that can detect the specific p-tau of CTE are needed.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2023)

Add to Collection

Article Biochemistry & Molecular Biology

Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial

Catherine J. Mummery et al.

Summary: By inhibiting MAPT expression with a tau-targeting antisense oligonucleotide (MAPTRx), researchers were able to reduce tau levels in patients with mild Alzheimer's disease. A randomized, double-blind trial found that the CSF total-tau protein concentration decreased by more than 50% in patients treated with MAPTRx, with mild adverse effects reported.

NATURE MEDICINE (2023)

Add to Collection

Article Clinical Neurology

Buntanetap, a Novel Translational Inhibitor of Multiple Neurotoxic Proteins, Proves to Be Safe and Promising in Both Alzheimer's and Parkinson's Patients

C. Fang et al.

Summary: This study evaluated the safety, pharmacokinetics, biomarkers, and efficacy of buntanetap in early AD and PD patients. The results showed that buntanetap was well tolerated and had a trend of reducing levels of neurotoxic proteins and inflammatory factors, as well as improving axonal integrity and synaptic function. Statistically significant improvements were also observed in psychometric tests.

JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE (2023)

Add to Collection

Review Clinical Neurology

Disclosing tau tangles using PET imaging: a pharmacological review of the radiotracers available in 2021

Eleonore Van Wambeke et al.

Summary: Neurological symptoms depend on the lesions' location in the nervous system, highlighting the importance of brain imaging for neurologists. Treatment, on the other hand, depends on the biological nature of the lesions. Developing radiotracers specific for proteinopathies in neurodegenerative disorders is crucial for understanding the relationships between pathology, clinical symptoms, and therapeutic interventions.

ACTA NEUROLOGICA BELGICA (2022)

Add to Collection

Review Clinical Neurology

Current directions in tau research: Highlights from Tau 2020

Claire Sexton et al.

Summary: Studies have shown a strong association between tau deposition and neuronal loss, neurodegeneration, and cognitive decline, leading to increased interest in tau and tau-related mechanisms as therapeutic targets. The first-ever Tau2020 Global Conference held in Washington, DC in February 2020 brought together leading experts from around the world to discuss recent advances and current directions in tau research, fostering global partnerships and supporting new drug discovery programs and emerging tau researchers. The meeting also presented critical research-advancing tools and insights that are accelerating the pace of tau research.

ALZHEIMERS & DEMENTIA (2022)

Add to Collection

Article Clinical Neurology

18F-MK-6240 tau-PET in genetic frontotemporal dementia

Jake P. Levy et al.

Summary: This study demonstrates promising potential for F-18-MK-6240 PET tracer in detecting tau in genetic frontotemporal dementia, with significant binding in P301L and R406W MAPT mutation subjects and no non-specific binding observed. The results suggest that a positive F-18-MK-6240 tau-PET does not necessarily indicate Alzheimer's disease diagnosis and may have applications in tauopathies beyond Alzheimer's.

BRAIN (2022)

Add to Collection

Review Clinical Neurology

A critical appraisal of tau-targeting therapies for primary and secondary tauopathies

Bruno P. Imbimbo et al.

Summary: Primary tauopathies are neurological disorders characterized by tau protein deposition, while Alzheimer's disease is a secondary tauopathy. Current drugs targeting tau have not shown clinical efficacy, potentially due to clearing of physiological forms of tau. Future research focuses on developing reliable animal models and selective compounds targeting specific tau epitopes and neurotoxic tau aggregates.

ALZHEIMERS & DEMENTIA (2022)

Add to Collection

Editorial Material Clinical Neurology

Diagnosing ALS: the Gold Coast criteria and the role of EMG

Martin R. Turner

PRACTICAL NEUROLOGY (2022)

Add to Collection

Review Anatomy & Morphology

Apoptosis and its therapeutic implications in neurodegenerative diseases

Nour S. Erekat

Summary: Neurodegenerative disorders involve the progressive loss of specific populations of neurons, with apoptosis playing a role in diseases such as Parkinson's, Alzheimer's, Huntington's, and ALS. This review examines the morphological features, mediators, and regulators of cellular apoptosis, highlighting evidence of neuronal apoptotic death in these diseases. The potential for therapeutic agents to modify the apoptotic pathway and delay disease progression is also discussed.

CLINICAL ANATOMY (2022)

Add to Collection

Review Neurosciences

Neurofilament Light Chain Levels in Frontotemporal Dementia and Progressive Supranuclear Palsy: A Systematic Review

Nathalie Bendstrup et al.

Summary: This systematic review evaluated the utility of neurofilament light in cerebrospinal fluid (CSF) for differentiating frontotemporal dementia (FTD) from progressive supranuclear palsy (PSP). The majority of studies included in this review found a higher level of neurofilament light in CSF in patients with FTD compared to patients with PSP; however, the results were inconsistent, indicating a need for further prospective studies.

JOURNAL OF ALZHEIMERS DISEASE (2022)

Add to Collection

Review Neurosciences

Alzheimer's Disease: Key Insights from Two Decades of Clinical Trial Failures

C. Kwon Kim et al.

Summary: This review examines the failures in Alzheimer's disease drug development over the past two decades and derives key insights for future drug development. The success rate of AD drugs has been only 2.0% since 2003, with reasons for clinical trial failures including lack of evidence to initiate pivotal trials and design shortcomings. It is recommended that future AD therapeutic development should adhere to rational drug development principles.

JOURNAL OF ALZHEIMERS DISEASE (2022)

Add to Collection

Review Clinical Neurology

The tauopathies: Neuroimaging characteristics and emerging experimental therapies

Kalen J. Riley et al.

Summary: Tauopathies are a group of neurodegenerative disorders characterized by the deposition of misfolded tau protein. Clinical diagnosis and anatomical imaging findings are challenging for specific tauopathies, while molecular biomarkers offer promise for patient care and emerging diagnostic and therapeutic applications. Tau-PET imaging using novel ligands targeting tau protein is an exciting development in assessing tau deposition in the brain.

JOURNAL OF NEUROIMAGING (2022)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Tau PET Imaging in Neurodegenerative Disorders

Colin Groot et al.

Summary: The introduction of PET ligands that bind tau pathology has allowed for the quantification and visualization of tau pathology in aging and Alzheimer's disease. While these ligands are effective in binding tau aggregates in advanced stages of AD, their binding in non-AD tauopathies is weaker and overlaps with known off-target binding regions. An increased neocortical tau PET signal holds important prognostic information, and tau PET shows great potential as a prognostic marker in symptomatic stages of AD. For differential diagnosis, tau PET is primarily useful in distinguishing AD dementia from other neurodegenerative diseases, but its performance decreases in the mild cognitive impairment stage of AD.

JOURNAL OF NUCLEAR MEDICINE (2022)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

18F-PI-2620 Tau PET Improves the Imaging Diagnosis of Progressive Supranuclear Palsy

Konstantin Messerschmidt et al.

Summary: This study investigates the potential of F-18-PI-2620 tau PET in improving the imaging diagnosis of PSP. The results show that adding F-18-PI-2620 tau PET to structural MRI can improve the accuracy of PSP imaging diagnosis, especially in early stages of the disease.

JOURNAL OF NUCLEAR MEDICINE (2022)

Add to Collection

Review Radiology, Nuclear Medicine & Medical Imaging

The Role of Amyloid PET in Imaging Neurodegenerative Disorders: A Review

Marianne Chapleau et al.

Summary: This article provides an up-to-date overview of the application of amyloid PET in neurodegenerative diseases, including analysis of clinical, pathological, and imaging data, comparison with other available biomarkers, and review of its use in clinical trials and clinical utility studies.

JOURNAL OF NUCLEAR MEDICINE (2022)

Add to Collection

Review Neurosciences

Tauopathies: new perspectives and challenges

Yi Zhang et al.

Summary: In this article, emerging knowledge on tauopathies from clinical, pathological, genetic, and experimental studies is synthesized to accelerate the development of therapeutics for these diseases. The focus is on depicting pathological characteristics, identifying biomarkers, elucidating the underlying pathogenesis for early diagnosis, and the development of disease-modifying therapies.

MOLECULAR NEURODEGENERATION (2022)

Add to Collection

Article Biochemistry & Molecular Biology

CSF tau microtubule-binding region identifies pathological changes in primary tauopathies

Kanta Horie et al.

Summary: Currently, there are no fluid biomarkers or imaging tracers available for the diagnosis and treatment of other tauopathies. This study identifies specific tau species that increase in the brains of patients with CBD, PSP, FTLD-MAPT, and AD, but decrease in their cerebrospinal fluid. Measurements of these specific tau species in cerebrospinal fluid can differentiate between different diseases and aid in the diagnosis and clinical trial design of primary tauopathies.

NATURE MEDICINE (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Tau as a Biomarker of Neurodegeneration

Sarah Holper et al.

Summary: The advances in tau detection have revolutionized the diagnosis of neurodegenerative diseases, offering improved diagnostic accuracy and potential as a predictor of clinical progression and drug therapy response.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Add to Collection

Review Neurosciences

Amyloid ?, Tau, and ?-Synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases

Urmi Sengupta et al.

Summary: This review summarizes the histopathological features of specific protein aggregation in several neurodegenerative diseases and discusses their overlap. It also highlights the synergistic interplay among Aβ, tau, and alpha-Syn in these diseases, suggesting a protein triumvirate.

PROGRESS IN NEUROBIOLOGY (2022)

Add to Collection

Review Clinical Neurology

Clinical Spectrum of Tauopathies

Nahid Olfati et al.

Summary: Tauopathies are diverse neurological disorders characterized by the accumulation of misfolded tau protein. The clinical presentation of tauopathies can vary widely, making it challenging to accurately diagnose and differentiate between different pathologies based on clinical findings. Further research is needed to validate the use of biomarkers and improve our understanding of the clinical-pathological correlations.

FRONTIERS IN NEUROLOGY (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Phosphorylated Tau in Alzheimer's Disease and Other Tauopathies

Priyanka Rawat et al.

Summary: This article summarizes the role of tau and phosphorylated tau (p-tau) in Alzheimer's disease (AD) and other tauopathies, highlighting current research on post-translational modifications and genetics of tau, tau pathology, the role of tau in tauopathies, and the development of new drugs targeting p-tau for therapeutics.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Temporal order of clinical and biomarker changes in familial frontotemporal dementia

Adam M. Staffaroni et al.

Summary: This study developed multimodal models for familial frontotemporal dementia (f-FTD) progression and found that the temporal ordering of clinical and biomarker progression differed by genotype. In prevention-trial simulations, atrophy and NfL were identified as the best endpoints, with clinical measures potential endpoints in early symptomatic trials.

NATURE MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS

Timothy M. Miller et al.

Summary: This study examined the use of tofersen in patients with SOD1 ALS and found that it can reduce protein concentrations in the cerebrospinal fluid and plasma, but does not improve clinical outcomes and is associated with adverse events. Further investigation is needed to evaluate the effects of early initiation of tofersen.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Clinical Neurology

Distinguishing Frontotemporal Lobar Degeneration Tau From TDP-43 Using Plasma Biomarkers

Katheryn A. Q. Cousins et al.

Summary: The plasma ratio of GFAP/NfL may differentiate between FTLD-tau and FTLD-TDP.

JAMA NEUROLOGY (2022)

Add to Collection

Review Medicine, General & Internal

Biomarkers for Alzheimer's Disease: Context of Use, Qualification, and Roadmap for Clinical Implementation

Jeffrey Cummings et al.

Summary: This review explores the regulatory guidance for the use of biomarkers in clinical trials and clinical care. Biomarkers used in clinical trials must have a defined context of use and follow a specific regulatory pathway. In clinical care, biomarkers can be companion biomarkers, in vitro diagnostic devices, or laboratory developed tests.

MEDICINA-LITHUANIA (2022)

Add to Collection

Review Clinical Neurology

Alzheimer's disease drug development pipeline: 2022

Jeffrey Cummings et al.

Summary: Alzheimer's disease is a global health crisis, and there are numerous clinical trials and drugs in development to treat and improve the symptoms and progression of the disease. The pipeline of drug development includes a diverse array of treatments, including disease-modifying therapies, cognitive enhancing treatments, and drugs for neuropsychiatric symptoms. Advances in drug design, outcome measures, biomarker use, and trial conduct show promise in accelerating the delivery of new and improved treatments for Alzheimer's disease patients.

ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS (2022)

Add to Collection

Article Clinical Neurology

Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease

S. Budd Haeberlein et al.

Summary: Aducanumab showed significant changes in early Alzheimer's disease patients in one trial, but did not meet primary or secondary endpoints in another study. Both trials demonstrated a dose- and time-dependent reduction in pathophysiological markers of Alzheimer's disease.

JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE (2022)

Add to Collection

Review Clinical Neurology

Disease-Modifying Therapies for Alzheimer's Disease: More Questions than Answers

Todd E. Golde

Summary: Scientific advances have brought optimism to the field of Alzheimer's disease, but the disease is still largely untreatable. The article reviews the major therapeutic approaches and open questions, and discusses the need to adjust our approach to ensure future success.

NEUROTHERAPEUTICS (2022)

Add to Collection

Review Geriatrics & Gerontology

The Role of Neuropsychiatric Symptoms in Research Diagnostic Criteria for Neurodegenerative Diseases

Jeffrey Cummings

Summary: Neuropsychiatric syndromes and symptoms are playing increasingly important roles in research diagnostic criteria for neurodegenerative disorders. They are often core diagnostic criteria, and the relationships between neuropsychiatric symptoms and cognitive, motor, and autonomic symptoms are being studied and better understood.

AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY (2021)

Add to Collection

Review Chemistry, Medicinal

Small molecule therapeutics for tauopathy in Alzheimer's disease: Walking on the path of most resistance

Lisha Wang et al.

Summary: Alzheimer's disease, characterized by amyloid plaques and tau tangles, affects millions worldwide with a lack of disease modifying therapies, leading to a growing burden on the economy and patients' quality of life. Development of new treatments targeting tau modification is urgently needed to address this challenge.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)

Add to Collection

Article Clinical Neurology

CSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer's disease

Kanta Horie et al.

Summary: The study analyzed MTBR-Tau species in Alzheimer's disease and control CSF using sequential immunoprecipitation and chemical extraction methods followed by mass spectrometry. The species containing the region beginning at residue 243 were found to be highly correlated with tau PET and cognitive measures. This suggests that CSF level of tau species containing the upstream region of MTBR may serve as biomarkers to stage Alzheimer's disease and track the development of tau-directed therapeutics.

BRAIN (2021)

Add to Collection

Article Clinical Neurology

Plasma Tau and Neurofilament Light in Frontotemporal Lobar Degeneration and Alzheimer Disease

Ignacio Illan-Gaia et al.

Summary: Plasma NfL outperforms plasma t-tau in distinguishing between FTLD-S and AD-S, predicting clinical decline and survival, and correlating with regional cortical thickness; while plasma t-tau shows inferior performance in these aspects.

NEUROLOGY (2021)

Add to Collection

Article Neurosciences

High-Contrast In Vivo Imaging of Tau Pathologies in Alzheimer's and Non-Alzheimer's Disease Tauopathies

Kenji Tagai et al.

Summary: A panel of radiochemicals for in vivo PET imaging of tau pathologies in AD has been developed, but sensitive detection of FTLD tau inclusions remains challenging. The imaging probe PM-PBB3 successfully captures diverse tau deposits in AD and FTLD, with increased binding observed in diseased patients in a subsequent clinical PET study. Visual inspection of F-18-PM-PBB3-PET images aids in individually based identification of diverse clinical phenotypes of FTLD on a neuropathological basis.

NEURON (2021)

Add to Collection

Article Multidisciplinary Sciences

Structure-based classification of tauopathies

Yang Shi et al.

Summary: The structures of tau filaments from different tauopathies vary, allowing for a hierarchical classification of these diseases. Some tauopathies share similar filament folds, while others have distinct folding patterns.

NATURE (2021)

Add to Collection

News Item Biotechnology & Applied Microbiology

Novartis's canakinumab stumbles in cancer, again

Asher Mullard

NATURE REVIEWS DRUG DISCOVERY (2021)

Add to Collection

Article Neurosciences

Relationships Between Cognition and Neuropathological Tau in Alzheimer's Disease Assessed by 18F Flortaucipir PET

Michael D. Devous et al.

Summary: The study revealed a significant inverse correlation between flortaucipir SUVr values and cognitive scores in specific domains, supporting the hypothesis that PET imaging may reflect neurodegeneration in AD.

JOURNAL OF ALZHEIMERS DISEASE (2021)

Add to Collection

Article Clinical Neurology

Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial

Guenter U. Hoeglinger et al.

Summary: This study evaluated the safety and efficacy of tilavonemab in treating progressive supranuclear palsy, a neurodegenerative disorder. However, no beneficial treatment effects were observed and the study was terminated due to futility criteria being met. The findings suggest a similar safety profile across all treatment groups, with potential implications for future investigations using tau antibodies for progressive supranuclear palsy.

LANCET NEUROLOGY (2021)

Add to Collection

Review Neurosciences

Moving fluid biomarkers for Alzheimer's disease from research tools to routine clinical diagnostics

Henrik Zetterberg et al.

Summary: Four fluid-based biomarkers have been developed as diagnostic tests for AD pathology, including markers for plaque pathology, AD-related changes in tau metabolism, and neurodegeneration. These biomarkers can be measured in cerebrospinal fluid or blood samples, aiding in the diagnosis of mild cognitive impairment or dementia due to AD.

MOLECULAR NEURODEGENERATION (2021)

Add to Collection

Article Medicine, General & Internal

Donanemab in Early Alzheimer's Disease

Mark A. Mintun et al.

Summary: In this study, donanemab showed improved composite scores for cognition and daily living activities compared to placebo in patients with early Alzheimer's disease at 76 weeks, although secondary outcomes varied. Longer and larger trials are needed to further explore the efficacy and safety of donanemab in Alzheimer's disease.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Review Multidisciplinary Sciences

Tau: Enabler of diverse brain disorders and target of rapidly evolving therapeutic strategies

Che-Wei Chang et al.

Summary: Evidence suggests that the protein tau plays a role in the pathogenesis of various brain disorders, but the specific functions and contributions of abnormal tau species in different disease models pose challenges to developing effective therapeutic strategies.

SCIENCE (2021)

Add to Collection

Review Chemistry, Medicinal

Tauvid (TM): The First FDA-Approved PET Tracer for Imaging Tau Pathology in Alzheimer's Disease

Caitlin V. M. L. Jie et al.

Summary: Tauvid, approved by the FDA in 2020 for PET imaging in AD patients, is a significant advancement in the field of AD research. This review summarizes the production, quality control, clinical application, pharmacology, and limitations of Tauvid, while also providing an overview of second-generation tau PET tracers.

PHARMACEUTICALS (2021)

Add to Collection

Article Clinical Neurology

Comparison of plasma neurofilament light and total tau as neurodegeneration markers: associations with cognitive and neuroimaging outcomes

Jordan D. Marks et al.

Summary: Plasma NfL is more strongly associated with cognitive and neuroimaging outcomes, while T-tau adds cross-sectional value when used in combination with NfL in specific contexts.

ALZHEIMERS RESEARCH & THERAPY (2021)

Add to Collection

Review Neurosciences

Neurofilament Proteins as Biomarkers to Monitor Neurological Diseases and the Efficacy of Therapies

Aidong Yuan et al.

Summary: Neurofilament proteins serve as important biomarkers of neurodegeneration and neuronal injury, reflecting neuronal damage and degeneration across various neurological diseases. Measuring NfP levels in cerebrospinal fluid and blood can track disease progression, assess treatment responses, and offer novel insights into a wide range of neurological disorders in the field of neurology.

FRONTIERS IN NEUROSCIENCE (2021)

Add to Collection

Review Neurosciences

Fluid Biomarkers in Clinical Trials for Alzheimer's Disease: Current and Future Application

Jianwei Yang et al.

Summary: AD research is currently at a crucial point where the molecular understanding of the disease is being translated into potential therapies, despite previous failures in drug development. Biomarkers measured in cerebrospinal fluid and blood are playing an increasingly important role in clinical trials for AD, reflecting the pathophysiological processes in the brain. Challenges in incorporating these biomarkers into trials have been acknowledged, but progress is being made to overcome these obstacles. Ongoing efforts in this area will be crucial for the development of disease-modifying treatments for AD.

JOURNAL OF ALZHEIMERS DISEASE (2021)

Add to Collection

Article Clinical Neurology

Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer's disease pathology and clinical disease progression

Christopher Clark et al.

Summary: Plasma NfL indicates neurodegeneration while plasma p-tau181 levels can serve as a biomarker of cerebral AD pathology and cognitive decline. Their predictive performance depends on the presence of cognitive impairment.

ALZHEIMERS RESEARCH & THERAPY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial

Tien Dam et al.

Summary: In the conducted study, treatment with the anti-tau antibody gosuranemab for progressive supranuclear palsy did not show clinical benefit. Gosuranemab did not demonstrate efficacy compared to placebo in terms of PSP Rating Scale score and secondary endpoints. The study indicates that N-terminal tau neutralization does not result in clinical efficacy.

NATURE MEDICINE (2021)

Add to Collection

Article Clinical Neurology

CSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer's disease

Kanta Horie et al.

Summary: The study analyzed MTBR-tau species in CSF and found that tau species containing the upstream region of MTBR were highly correlated with tau PET and cognitive assessments in Alzheimer's disease, suggesting they could serve as biomarkers for staging Alzheimer's disease and tracking tau-directed therapeutics development.

BRAIN (2021)

Add to Collection

Article Clinical Neurology

Reactions to Multiple Ascending Doses of the Microtubule Stabilizer TPI-287 in Patients With Alzheimer Disease, Progressive Supranuclear Palsy, and Corticobasal Syndrome A Randomized Clinical Trial

Richard M. Tsai et al.

JAMA NEUROLOGY (2020)

Add to Collection

Article Multidisciplinary Sciences

Novel tau filament fold in corticobasal degeneration

Wenjuan Zhang et al.

NATURE (2020)

Add to Collection

Article Clinical Neurology

Redefining the multidimensional clinical phenotypes of frontotemporal lobar degeneration syndromes

Alexander G. Murley et al.

BRAIN (2020)

Add to Collection

Article Neurosciences

Concentration-Dependent Activity of Hydromethylthionine on Clinical Decline and Brain Atrophy in a Randomized Controlled Trial in Behavioral Variant Frontotemporal Dementia

Helen Shiells et al.

JOURNAL OF ALZHEIMERS DISEASE (2020)

Add to Collection

Review Clinical Neurology

Research criteria for the diagnosis of prodromal dementia with Lewy bodies

Ian G. McKeith et al.

NEUROLOGY (2020)

Add to Collection

Article Clinical Neurology

Comparing progression biomarkers in clinical trials of early Alzheimer's disease

Nicholas C. Cullen et al.

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2020)

Add to Collection

Review Biochemistry & Molecular Biology

Tauopathies: Deciphering Disease Mechanisms to Develop Effective Therapies

M. Catarina Silva et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

Add to Collection

Article Neurosciences

Regional binding of tau and amyloid PET tracers in Down syndrome autopsy brain tissue

L. Lemoine et al.

MOLECULAR NEURODEGENERATION (2020)

Add to Collection

Article Multidisciplinary Sciences

Small molecule modulation of the p75 neurotrophin receptor inhibits multiple amyloid beta-induced tau pathologies

Tao Yang et al.

SCIENTIFIC REPORTS (2020)

Add to Collection

Review Neurosciences

New Insights Into Drug Discovery Targeting Tau Protein

Yoshiyuki Soeda et al.

FRONTIERS IN MOLECULAR NEUROSCIENCE (2020)

Add to Collection

Review Clinical Neurology

Tauopathy and Movement Disorders-Unveiling the Chameleons and Mimics

Jacky Ganguly et al.

FRONTIERS IN NEUROLOGY (2020)

Add to Collection

Review Clinical Neurology

Tau Filament Self-Assembly and Structure: Tau as a Therapeutic Target

Sebastian S. Oakley et al.

FRONTIERS IN NEUROLOGY (2020)

Add to Collection

Article Neurosciences

Pre-clinical characterisation of E2814, a high-affinity antibody targeting the microtubule-binding repeat domain of tau for passive immunotherapy in Alzheimer's disease

Malcolm Roberts et al.

ACTA NEUROPATHOLOGICA COMMUNICATIONS (2020)

Add to Collection

Article Multidisciplinary Sciences

Novel tau filament fold in chronic traumatic encephalopathy encloses hydrophobic molecules

Benjamin Falcon et al.

NATURE (2019)

Add to Collection

Article Clinical Neurology

18F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes

Richard M. Tsai et al.

ALZHEIMERS RESEARCH & THERAPY (2019)

Add to Collection

Review Clinical Neurology

Neurofilament light chain as a biomarker in neurological disorders

Lorenzo Gaetani et al.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2019)

Add to Collection

Review Neurosciences

The complexity of tau in Alzheimer's disease

Nima N. Naseri et al.

NEUROSCIENCE LETTERS (2019)

Add to Collection

Review Clinical Neurology

The rights of precision drug development for Alzheimer's disease

Jeffrey Cummings et al.

ALZHEIMERS RESEARCH & THERAPY (2019)

Add to Collection

Article Neurosciences

Biomarkers for tau pathology

Michael Scholl et al.

MOLECULAR AND CELLULAR NEUROSCIENCE (2019)

Add to Collection

Article Cell Biology

Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases

Michael G. Erkkinen et al.

COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2018)

Add to Collection

Review Clinical Neurology

NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease

Clifford R. Jack et al.

ALZHEIMERS & DEMENTIA (2018)

Add to Collection

Editorial Material Medicine, Research & Experimental

It's Time to Reverse our Thinking: The Reverse Translation Research Paradigm

Valentina Shakhnovich

CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2018)

Add to Collection

Article Medicine, Research & Experimental

Biomarker definitions and their applications

Robert M. Califf

EXPERIMENTAL BIOLOGY AND MEDICINE (2018)

Add to Collection

Article Clinical Neurology

Serum neurofilament light chain in progressive supranuclear palsy

Laura Donker Kaat et al.

PARKINSONISM & RELATED DISORDERS (2018)

Add to Collection

Article Multidisciplinary Sciences

Structures of filaments from Pick's disease reveal a novel tau protein fold

Benjamin Falcon et al.

NATURE (2018)

Add to Collection

Review Clinical Neurology

Tau Imaging in Alzheimer's Disease Diagnosis and Clinical Trials

Jared R. Brosch et al.

NEUROTHERAPEUTICS (2017)

Add to Collection

Article Clinical Neurology

Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches

Adam L. Boxer et al.

LANCET NEUROLOGY (2017)

Add to Collection

Review Biotechnology & Applied Microbiology

Tau-based therapies in neurodegeneration: opportunities and challenges

Chuanzhou Li et al.

NATURE REVIEWS DRUG DISCOVERY (2017)

Add to Collection

Article Cell Biology

Pathology of Neurodegenerative Diseases

Brittany N. Dugger et al.

COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2017)

Add to Collection

Article Clinical Neurology

Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease

Alexandre Bejanin et al.

BRAIN (2017)

Add to Collection

Article Clinical Neurology

Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies

Maiko Ono et al.

BRAIN (2017)

Add to Collection

Review Clinical Neurology

True alignment of preclinical and clinical research to enhance success in CNS drug development: a review of the current evidence

Pascal J. D. Goetghebeur et al.

JOURNAL OF PSYCHOPHARMACOLOGY (2016)

Add to Collection

Article Clinical Neurology

Primary age-related tauopathy (PART): a common pathology associated with human aging

John F. Crary et al.

ACTA NEUROPATHOLOGICA (2014)

Add to Collection

Review Clinical Neurology

Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature

Peter T. Nelson et al.

JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2012)

Add to Collection

Review Neurosciences

Tau protein isoforms, phosphorylation and role in neurodegenerative disorders

L Buée et al.

BRAIN RESEARCH REVIEWS (2000)

Add to Collection

© Peeref 2019-2024. All rights reserved.